Journal of Controlled Release 76 (2001) 383–384www.elsevier.com/ locate / jconrel

Subject Index Volume 76 (2001)

Absorption enhancer, (76) 369 Fluorescence de-quenching, (76) 27Acetone, (76) 327 Fluorescence energy transfer, (76) 27Affinity, (76) 129Alanine, (76) 265 Galactosylated chitosan, (76) 349Albumin, (76) 107 Gel, (76) 337Alkyl-substituted silica xerogel, (76) 227 Glycine, (76) 265Anticancer agent, (76) 239Antitumoral agent, (76) 107

Hepatocyte targeting, (76) 349Asialoglycoprotein receptors, (76) 349High amylose starch, (76) 51Aspirin, (76) 39High drug loading, (76) 51Azone, (76) 327hPepT1, (76) 129Hyaluronan, (76) 337Blood–brain barrier (BBB), (76) 139Hydrocortisone, (76) 327Bovine serum albumin, (76) 275Hydrogel, (76) 11Brain capillaries endothelial cells (ECs), (76) 139Hydroxypropyl methylcellulose, (76) 39

Caco-2, (76) 1Immunotoxin, (76) 285Calcitonin, (76) 369

In vivo, (76) 227Carbopol 974 P, (76) 81In-vitro cytotoxicity, (76) 285Confocal laser scanning microscopy, (76) 59Intralipid, (76) 1Conjugate addition, (76) 11Iontophoresis, (76) 73Controlled release, (76) 255

Coordinate bond, (76) 337

KALA, (76) 183Dendritic cells, (76) 59, (76) 149 Kinetics of drug release, (76) 209Dexmedetomidine, (76) 227Dipeptide model prodrugs, (76) 129 LIPIDSL-DOPA, (76) 139Dissolution, (76) 119

L-Tryptophan, (76) 139, (76) 327DNA, (76) 149 Lipoplex, (76) 169DNA carrier, (76) 349 Liposomes, (76) 1DNA complex, (76) 169DNA delivery, (76) 183

Macromolecular-drug conjugate, (76) 107DNA digestion, (76) 169Macrophages, (76) 59, (76) 149DNA stability, (76) 169Matrix tablet, (76) 39Dopamine, (76) 139Mean particle size, (76) 39Doxycycline, (76) 337Michael-type addition, (76) 11Drug absorption, (76) 369Microcapsule, (76) 313Drug controlled release, (76) 51Microparticle, (76) 275Microspheres, (76) 199, (76) 239, (76) 297Emulsifiers, (76) 239Monensin liposomes, (76) 285Emulsion, (76) 119

Epirubicin, (76) 1Erosion mechanism, (76) 297 N-isopropylacrylamide-acrylic acid oligomer, (76) 265Excipients, (76) 51 Nanoparticles, (76) 119

PII : S0168-3659( 01 )00465-5

384 Subject Index Volume 76 (2001)

Nasal and mucosal toxicity, (76) 81 QSAR, (76) 129Non-aqueous encapsulation, (76) 199Non-viral vector, (76) 183 Rabbits, (76) 81Number of particles, (76) 39 Rat intestines, (76) 1

Release test, (76) 337Oily core, (76) 313Ophthalmic insert, (76) 255 Serine, (76) 265

Skin, (76) 327Paclitaxel, (76) 107, (76) 239 Slugs, (76) 81PEG, (76) 183, (76) 349 Sodium lauryl sulfate, (76) 327PEI, (76) 183 Sol–gel-processed silica xerogel, (76) 227Peptide drug delivery, (76) 369 Solvent quenching, (76) 119P-Glycoprotein, (76) 1 Span of distribution, (76) 39pH, (76) 327 Spray dry, (76) 239pH-gradient method, (76) 285 Spray-freeze drying, (76) 199Phagocytosis, (76) 59 Starch derivatives, (76) 51Piroxicam, (76) 73 Starch, (76) 81PLGA degradation, (76) 297 Stratum corneum, (76) 73, (76) 327PLLA-g-oligoEG, (76) 275 Superoxide radical anion, (76) 209Pluronic F127, (76) 27 Surface erosion, (76) 209Poly(ethylene carbonate)s, (76) 209 Surface modified particles, (76) 59Poly(ethylene glycol), (76) 107, (76) 11Poly(lactide-co-glycolide) (PLGA) microspheres, (76) 149 Temperature and pH responsive, (76) 265Poly(lactide-co-glycolide), (76) 199, (76) 313 Temperature-controlled release, (76) 27Poly(e-caprolactone), (76) 313 Testosterone, (76) 327Polymer degradation, (76) 275 Tilisolol, (76) 255Polyplex, (76) 169 Topical drug bioavailability, (76) 73Pore size, (76) 297 Toxicity, (76) 149Prodrugs, (76) 255 Transdermal drug delivery, (76) 73Protein aggregation, (76) 199 Transmucosal drug delivery, (76) 369Protein delivery, (76) 11 Transport, (76) 129Protein molecular weight, (76) 297 Trypan blue quenching, (76) 59Protein release, (76) 275, (76) 313

PSC 833, (76) 1